Christian Meyer
Direttore operativo presso VectivBio AG
Provenienza dei contatti di primo grado di Christian Meyer
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
29
| Public Company | Biotechnology | 29 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.
8
| Subsidiary | Biotechnology | 8 |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
2
| Extinct | Biotechnology | 2 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Christian Meyer tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Public Communications Contact Corporate Officer/Principal | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
CDC Enterprises, Inc.
 CDC Enterprises, Inc. Electrical ProductsProducer Manufacturing CDC Enterprises, Inc. designs, manufactures, and distributes patented HDPE ductwork products. It offers airtight, mildew, corrosion resistant, and thermal constructed ductwork products. The firm specializes in electrical instrumentation, controls and systems integration, for public works, utilities, private industry, and government organizations. It provides a wide range of services including pump efficiency monitoring, system diagnostics and troubleshooting, GPS mapping, robotic controls, panel design, and fabrication. The company was founded by Jon W. Jungers in April 2001 and is headquartered in Ringwood, IL. | Electrical Products | Chief Tech/Sci/R&D Officer | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Stanford University | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| Louisiana State University | College/University | Corporate Officer/Principal Doctorate Degree | |
| Loyola University of Chicago | College/University | Undergraduate Degree Doctorate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Corporate Officer/Principal | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
| Institut National Agronomique Paris-Grignon | College/University | Graduate Degree | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| MOLECULAR PARTNERS AG | Biotechnology | Chairman Director/Board Member | |
| BANCO SANTANDER, S.A. | Major Banks | Corporate Officer/Principal | |
INSERM Transfert Initiative SAS
 INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Investment Managers | Chairman | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Juvenile Diabetes Research Foundation Canada
 Juvenile Diabetes Research Foundation Canada Miscellaneous Commercial ServicesCommercial Services Juvenile Diabetes Research Foundation Canada focuses on type 1 diabetes (T1D) research. The company was founded in 1974 and is headquartered in Toronto, Canada. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| SENSORION | Pharmaceuticals: Major | Director/Board Member | |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
| PIXIUM VISION | Medical Specialties | Director/Board Member | |
| SYROS PHARMACEUTICALS, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| LYSOGENE | Miscellaneous Commercial Services | Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member | |
In Situ Training SAS
 In Situ Training SAS Miscellaneous Commercial ServicesCommercial Services In Situ Training SAS provides medical training services. It specializes in e-medicine, Medical Training, In Situ Training, Digital Health, e-health and Training inside the OR. The company was founded by Patxi Ospital and Julien Delpech in 2015 and is headquartered in Pessac, France. | Miscellaneous Commercial Services | Director/Board Member | |
Brainever SAS
 Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Incepto Medical SAS
 Incepto Medical SAS Packaged SoftwareTechnology Services Incepto Medical SAS develops and distributes artificial intelligent (AI) based medical imaging applications. It offers solutions for computed tomography (CT) scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion. The company was founded by Antoine Jomier, Florence Moreau, Vincent Barrau, Jean Michel Malbrancq, and Gaspard d’Assignies and is headquartered in Paris, France. | Packaged Software | Director/Board Member | |
Doctoconsult SAS
 Doctoconsult SAS Internet Software/ServicesTechnology Services Doctoconsult SAS operates an online portal, which provides telemedecine services. It specializes in mental health. The company was founded by Grevent Fanny Jacq in 2016 and is headquartered in Fresnes, France. | Internet Software/Services | Director/Board Member | |
| PASSAGE BIO, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
IEcure, Inc.
 IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Biotechnology | Director/Board Member Chief Operating Officer | |
| Arradial, Inc. | Director/Board Member Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Stati Uniti | 21 |
| Francia | 18 |
| Svizzera | 5 |
| Regno Unito | 4 |
| Paesi Bassi | 3 |
Settori
| Health Technology | 31 |
| Commercial Services | 7 |
| Consumer Services | 7 |
| Finance | 4 |
| Technology Services | 3 |
Posizioni
| Director/Board Member | 246 |
| Corporate Officer/Principal | 88 |
| Independent Dir/Board Member | 66 |
| Chairman | 35 |
| Chief Tech/Sci/R&D Officer | 34 |
Contatti più connessi
| Insiders | |
|---|---|
| Stephen P. Squinto | 40 |
| Thomas Woiwode | 39 |
| Hugo Slootweg | 34 |
| Chahra Khaoua Epouse Louafi | 26 |
| Ferdinand Verdonck | 25 |
| Joseph Feczko | 23 |
| Johannes G. C. P. Schikan | 22 |
| François Meyer | 20 |
| Sandipkumar S. Kapadia | 19 |
| Piers John Morgan | 18 |
| Madhavan Balachandran | 15 |
| David Schaffer | 15 |
| Jörn Aldag | 15 |
| Edwin de Graaf | 14 |
| Jeremy Springhorn | 14 |
- Borsa valori
- Insiders
- Christian Meyer
- Connessioni Società
